vimarsana.com

Page 22 - ஹைதராபாத் அடிப்படையிலானது பாரத் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Covid-19: Oxford vaccine may get nod in a few days | India News

A PTI report said the drug major s CEO Pascal Soriot has reported the Covishield vaccine to have achieved a “winning formula” for efficacy. Soriot’s comments were carried in an interview with the Sunday Times newspaper. He added that he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95% and Moderna at 94.5 per cent. “We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” the chief executive said, while only adding that data would be published at “some point”. He also said that the vaccine “should be” effective against the new highly transmissible variant of the coronavirus.

Covid vaccine update: US may approve Moderna vaccine too, AIIMS unable to find volunteers for Covaxin trials

UPDATED: December 18, 2020 10:03 IST Coronavirus vaccine update: After the Pfizer vaccine, US may now approve the Moderna vaccine as well. (Reuters) Coronavirus vaccine update: After rolling out the Pfizer coronavirus vaccine, US is now looking to approve the Moderna vaccine as well as coronavirus cases surge in the nation. An advisory panel of the US drug regulator has endorsed the Moderna vaccine. Meanwhile in India, AIIMS-Delhi is reportedly finding it difficult to get enough volunteers for the Phase 3 trials of Covaxin, a Covid-19 vaccine candidate being developed by Hyderabad-based Bharat Biotech. US FDA panel endorses Moderna vaccine With the United States battling another surge in Covid-19 cases and the nation seeing another 2,32,255 fresh coronavirus cases on Wednesday, the country is on path to approve a second coronavirus vaccine after it began the rollout of Pfizer vaccine last week.

Coronavirus outbreak: vaccine effect surveillance

India’s Covid-19 vaccination guidelines have proposed a nationwide surveillance network to detect and respond to possible adverse events after immunisation (AEFI) that experts say would be critical for evaluation of vaccines approved under emergency use authorisation. The guidelines prepared by the Union health ministry would require every vaccination session site across the country to be linked to an AEFI management centre located at a primary health centre, a community health centre, a district hospital or a private hospital. The AEFI surveillance would also require doctors to “ask and record” a history of Covid-19 vaccination in patients during out-patient or emergency consultations and report any symptoms that have occurred after immunisation telephonically to designated local health officials.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.